Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence.
Beni LestariIkuko NakamaeNoriko Yoneda-KatoTsumoru MorimotoShigehiko KanayaTakashi YokoyamaMasafumi ShionyuTsuyoshi ShiraiEdy MeiyantoJun-Ya KatoPublished in: Scientific reports (2019)
We previously showed that curcumin, a phytopolyphenol found in turmeric (Curcuma longa), targets a series of enzymes in the ROS metabolic pathway, induces irreversible growth arrest, and causes apoptosis. In this study, we tested Pentagamavunon-1 (PGV-1), a molecule related to curcumin, for its inhibitory activity on tumor cells in vitro and in vivo. PGV-1 exhibited 60 times lower GI50 compared to that of curcumin in K562 cells, and inhibited the proliferation of cell lines derived from leukemia, breast adenocarcinoma, cervical cancer, uterine cancer, and pancreatic cancer. The inhibition of growth by PGV-1 remained after its removal from the medium, which suggests that PGV-1 irreversibly prevents proliferation. PGV-1 specifically induced prometaphase arrest in the M phase of the cell cycle, and efficiently induced cell senescence and cell death by increasing intracellular ROS levels through inhibition of ROS-metabolic enzymes. In a xenograft mouse model, PGV-1 had marked anti-tumor activity with little side effects by oral administration, whereas curcumin rarely inhibited tumor formation by this administration. Therefore, PGV-1 is a potential therapeutic to induce tumor cell apoptosis with few side effects and low risk of relapse.
Keyphrases
- cell death
- cell cycle
- cell cycle arrest
- dna damage
- cell proliferation
- reactive oxygen species
- mouse model
- signaling pathway
- single cell
- high glucose
- endothelial cells
- oxidative stress
- squamous cell carcinoma
- diabetic rats
- induced apoptosis
- cell therapy
- drug induced
- acute myeloid leukemia
- papillary thyroid
- squamous cell
- rectal cancer